The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Malignant Pleural Mesothelioma Treatment Market Research Report 2025
Synopsis
Malignant pleural mesothelioma (MPM) is a relatively rare but aggressive form of cancer arising from the membrane covering the lungs and the inner side of the ribs. This type of cancer is most frequently a result of inhaling asbestos.
The global Malignant Pleural Mesothelioma Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Malignant Pleural Mesothelioma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Pleural Mesothelioma Treatment.
Report Scope
The Malignant Pleural Mesothelioma Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Malignant Pleural Mesothelioma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Malignant Pleural Mesothelioma Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Segment by Type
Pemetrexed
Cisplatin
Others
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Malignant Pleural Mesothelioma Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Malignant Pleural Mesothelioma Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Malignant pleural mesothelioma (MPM) is a relatively rare but aggressive form of cancer arising from the membrane covering the lungs and the inner side of the ribs. This type of cancer is most frequently a result of inhaling asbestos.
The global Malignant Pleural Mesothelioma Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Malignant Pleural Mesothelioma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Pleural Mesothelioma Treatment.
Report Scope
The Malignant Pleural Mesothelioma Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Malignant Pleural Mesothelioma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Malignant Pleural Mesothelioma Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Segment by Type
Pemetrexed
Cisplatin
Others
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Malignant Pleural Mesothelioma Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Malignant Pleural Mesothelioma Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Malignant Pleural Mesothelioma Treatment Market Overview
1.1 Product Overview and Scope of Malignant Pleural Mesothelioma Treatment
1.2 Malignant Pleural Mesothelioma Treatment Segment by Type
1.2.1 Global Malignant Pleural Mesothelioma Treatment Market Value Comparison by Type (2024-2030)
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Others
1.3 Malignant Pleural Mesothelioma Treatment Segment by Application
1.3.1 Global Malignant Pleural Mesothelioma Treatment Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Malignant Pleural Mesothelioma Treatment Market Size Estimates and Forecasts
1.4.1 Global Malignant Pleural Mesothelioma Treatment Revenue 2019-2030
1.4.2 Global Malignant Pleural Mesothelioma Treatment Sales 2019-2030
1.4.3 Global Malignant Pleural Mesothelioma Treatment Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Malignant Pleural Mesothelioma Treatment Market Competition by Manufacturers
2.1 Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Manufacturers (2019-2024)
2.2 Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Malignant Pleural Mesothelioma Treatment Average Price by Manufacturers (2019-2024)
2.4 Global Malignant Pleural Mesothelioma Treatment Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Malignant Pleural Mesothelioma Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Malignant Pleural Mesothelioma Treatment, Product Type & Application
2.7 Malignant Pleural Mesothelioma Treatment Market Competitive Situation and Trends
2.7.1 Malignant Pleural Mesothelioma Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Malignant Pleural Mesothelioma Treatment Players Market Share by Revenue
2.7.3 Global Malignant Pleural Mesothelioma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Malignant Pleural Mesothelioma Treatment Retrospective Market Scenario by Region
3.1 Global Malignant Pleural Mesothelioma Treatment Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Malignant Pleural Mesothelioma Treatment Global Malignant Pleural Mesothelioma Treatment Sales by Region: 2019-2030
3.2.1 Global Malignant Pleural Mesothelioma Treatment Sales by Region: 2019-2024
3.2.2 Global Malignant Pleural Mesothelioma Treatment Sales by Region: 2025-2030
3.3 Global Malignant Pleural Mesothelioma Treatment Global Malignant Pleural Mesothelioma Treatment Revenue by Region: 2019-2030
3.3.1 Global Malignant Pleural Mesothelioma Treatment Revenue by Region: 2019-2024
3.3.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Region: 2025-2030
3.4 North America Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Country
3.4.1 North America Malignant Pleural Mesothelioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Malignant Pleural Mesothelioma Treatment Sales by Country (2019-2030)
3.4.3 North America Malignant Pleural Mesothelioma Treatment Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Country
3.5.1 Europe Malignant Pleural Mesothelioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Malignant Pleural Mesothelioma Treatment Sales by Country (2019-2030)
3.5.3 Europe Malignant Pleural Mesothelioma Treatment Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific Malignant Pleural Mesothelioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Malignant Pleural Mesothelioma Treatment Sales by Country (2019-2030)
3.6.3 Asia Pacific Malignant Pleural Mesothelioma Treatment Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Country
3.7.1 Latin America Malignant Pleural Mesothelioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Malignant Pleural Mesothelioma Treatment Sales by Country (2019-2030)
3.7.3 Latin America Malignant Pleural Mesothelioma Treatment Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Malignant Pleural Mesothelioma Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Malignant Pleural Mesothelioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Malignant Pleural Mesothelioma Treatment Sales by Country (2019-2030)
3.8.3 Middle East and Africa Malignant Pleural Mesothelioma Treatment Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Malignant Pleural Mesothelioma Treatment Sales by Type (2019-2030)
4.1.1 Global Malignant Pleural Mesothelioma Treatment Sales by Type (2019-2024)
4.1.2 Global Malignant Pleural Mesothelioma Treatment Sales by Type (2025-2030)
4.1.3 Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Type (2019-2030)
4.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Type (2019-2030)
4.2.1 Global Malignant Pleural Mesothelioma Treatment Revenue by Type (2019-2024)
4.2.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Type (2025-2030)
4.2.3 Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Type (2019-2030)
4.3 Global Malignant Pleural Mesothelioma Treatment Price by Type (2019-2030)
5 Segment by Application
5.1 Global Malignant Pleural Mesothelioma Treatment Sales by Application (2019-2030)
5.1.1 Global Malignant Pleural Mesothelioma Treatment Sales by Application (2019-2024)
5.1.2 Global Malignant Pleural Mesothelioma Treatment Sales by Application (2025-2030)
5.1.3 Global Malignant Pleural Mesothelioma Treatment Sales Market Share by Application (2019-2030)
5.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Application (2019-2030)
5.2.1 Global Malignant Pleural Mesothelioma Treatment Revenue by Application (2019-2024)
5.2.2 Global Malignant Pleural Mesothelioma Treatment Revenue by Application (2025-2030)
5.2.3 Global Malignant Pleural Mesothelioma Treatment Revenue Market Share by Application (2019-2030)
5.3 Global Malignant Pleural Mesothelioma Treatment Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly Malignant Pleural Mesothelioma Treatment Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Teva Malignant Pleural Mesothelioma Treatment Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Malignant Pleural Mesothelioma Treatment Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Corporation Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bristol-Myers Squibb Malignant Pleural Mesothelioma Treatment Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Malignant Pleural Mesothelioma Treatment Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Roche Malignant Pleural Mesothelioma Treatment Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Malignant Pleural Mesothelioma Treatment Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Ono Pharmaceutical
6.8.1 Ono Pharmaceutical Corporation Information
6.8.2 Ono Pharmaceutical Description and Business Overview
6.8.3 Ono Pharmaceutical Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Ono Pharmaceutical Malignant Pleural Mesothelioma Treatment Product Portfolio
6.8.5 Ono Pharmaceutical Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Mylan Malignant Pleural Mesothelioma Treatment Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Fresenius Kabi
6.10.1 Fresenius Kabi Corporation Information
6.10.2 Fresenius Kabi Description and Business Overview
6.10.3 Fresenius Kabi Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Fresenius Kabi Malignant Pleural Mesothelioma Treatment Product Portfolio
6.10.5 Fresenius Kabi Recent Developments/Updates
6.11 Sun Pharmaceuticals
6.11.1 Sun Pharmaceuticals Corporation Information
6.11.2 Sun Pharmaceuticals Malignant Pleural Mesothelioma Treatment Description and Business Overview
6.11.3 Sun Pharmaceuticals Malignant Pleural Mesothelioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sun Pharmaceuticals Malignant Pleural Mesothelioma Treatment Product Portfolio
6.11.5 Sun Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Malignant Pleural Mesothelioma Treatment Industry Chain Analysis
7.2 Malignant Pleural Mesothelioma Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Malignant Pleural Mesothelioma Treatment Production Mode & Process
7.4 Malignant Pleural Mesothelioma Treatment Sales and Marketing
7.4.1 Malignant Pleural Mesothelioma Treatment Sales Channels
7.4.2 Malignant Pleural Mesothelioma Treatment Distributors
7.5 Malignant Pleural Mesothelioma Treatment Customers
8 Malignant Pleural Mesothelioma Treatment Market Dynamics
8.1 Malignant Pleural Mesothelioma Treatment Industry Trends
8.2 Malignant Pleural Mesothelioma Treatment Market Drivers
8.3 Malignant Pleural Mesothelioma Treatment Market Challenges
8.4 Malignant Pleural Mesothelioma Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
